Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Caitlin P. Oravec"'
Autor:
Mariana Albano, Melissa J. Karau, Kerryl E. Greenwood-Quaintance, Douglas R. Osmon, Caitlin P. Oravec, Daniel J. Berry, Matthew P. Abdel, Robin Patel
Publikováno v:
Microbiology Spectrum, Vol 9, Iss 1 (2021)
ABSTRACT After staphylococci, streptococci and enterococci are the most frequent causes of periprosthetic joint infection (PJI). MICs and minimum biofilm bactericidal concentrations of rifampin, rifabutin, and rifapentine were determined for 67 enter
Externí odkaz:
https://doaj.org/article/b4f4b18eaa21446e93591d07478476b1
Autor:
Gina A. Suh, Ryan W. Stevens, Caitlin P Oravec, Douglas R. Osmon, Abinash Virk, Elena Beam, Kristin C. Mara, Nicholas J Vollmer, Matthew P. Abdel, Christina G. Rivera
Publikováno v:
Clinical Infectious Diseases. 73:850-856
Background Fluoroquinolones (FQs) are known to be accompanied by significant risks. However, the incidence of adverse events (ADEs) resulting in unplanned drug discontinuation when used for periprosthetic joint infections (PJIs) is currently unknown.
Autor:
Caitlin P. Oravec, Douglas R. Osmon
It is important to obtain routine mycobacterial cultures in patients with a history of bacille Calmette-Guérin (BCG) treatment who present with culture-negative infection. BCG sepsis syndrome can develop a few days to months after instillations are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f37d390e6f648e84fcbc38806b2530b
https://doi.org/10.1093/med/9780190052973.003.0049
https://doi.org/10.1093/med/9780190052973.003.0049
Autor:
Melissa J. Karau, Mariana Albano, Matthew P. Abdel, Daniel J. Berry, Kerryl E. Greenwood-Quaintance, Douglas R. Osmon, Caitlin P Oravec, Robin Patel
Publikováno v:
Microbiology Spectrum, Vol 9, Iss 1 (2021)
Microbiology Spectrum
Microbiology Spectrum
After staphylococci, streptococci and enterococci are the most frequent causes of periprosthetic joint infection (PJI). MICs and minimum biofilm bactericidal concentrations of rifampin, rifabutin, and rifapentine were determined for 67 enterococcal a
Publikováno v:
American Journal of Health-System Pharmacy. 76:804-809
Purpose There are limited data on the effect of ceftriaxone on methotrexate clearance, with results of some studies indicating altered methotrexate pharmacokinetics with the administration of ceftriaxone. We describe 2 possible cases demonstrating an
Autor:
Augustine S. Lee, Erika L. Halverson, Mark J. Enzler, Jorge M. Mallea, Zelalem Temesgen, Mary J. Kasten, John C. O’Horo, Priya Sampathkumar, William G. Morice, John Raymond Go, Catherine Cate D Zomok, Douglas W. Challener, Henry H Ting, James J. Vaillant, Heather A. Heaton, Ayan Sen, William F. Marshall, Ravindra Ganesh, Edison J Cano Cevallos, Eva M. Carmona Porquera, Pramod Guru, Mariam Assi, Charles D. Burger, Mohamed Y Warsame, Anne M. Meehan, Natalie J Ough, Wendelyn Bosch, Michael F. Harrison, Hussam Tabaja, David M. Phelan, Joel E Gordon, Ryan T. Hurt, Raj Palraj, Natalia E Castillo Almeida, Ala S. Dababneh, Raymund R. Razonable, Aaron J. Tande, Hind J. Fadel, Gina A. Suh, Aditya Shah, Omar Abu Saleh, Jennifer J O'Brien, Pablo Moreno Franco, Cristina Corsini Campioli, Dennis M. Bierle, Sarah J. Crane, Alice Gallo De Moraes, Casey M. Clements, Bhavesh M. Patel, F. N.U. Shweta, Stacey A. Rizza, Isin Y. Comba, Paschalis Vergidis, Zachary A Yetmar, Caitlin P Oravec, Pooja Gurram, James R. Cerhan, Russell C Tontz, Kai Singbartl, Elie F. Berbari, Andy Abril, Leigh L. Speicher, Philippe R. Bauer, Jon O. Ebbert, Brian W. Pickering, Amy W. Williams, Elliot J. Cahn, Emily R Levy, Gautam Matcha, Robert Orenstein, Vincent S Pureza, Jason Siegel, Richard A. Oeckler, Devang Sanghavi, Steve R. Ommen, Supavit Chesdachai, Andrew D. Badley, Claudia R. Libertin
Publikováno v:
Mayo Clinic Proceedings
Objective To report the Mayo Clinic experience with coronavirus disease 2019 (COVID-19) related to patient outcomes. Methods We conducted a retrospective chart review of patients with COVID-19 diagnosed between March 1, 2020, and July 31, 2020, at an
Autor:
Robin Patel, Daniel J. Berry, Douglas R. Osmon, Suzannah M. Schmidt-Malan, Matthew P. Abdel, Christina G. Rivera, Caitlin P Oravec, Jayawant N. Mandrekar, Melissa J. Karau, Mariana Albano
Publikováno v:
The Journal of infectious diseases. 222(9)
Background Owing to patient intolerance or drug interactions, alternative agents to rifampin are needed for management of staphylococcal periprosthetic joint infection. In the current study, we evaluated rifabutin, rifapentine and rifampin, with and
Autor:
Melissa J. Karau, Mariana Albano, Caitlin P Oravec, Matthew P. Abdel, Robin Patel, Kerryl E. Greenwood-Quaintance, Daniel J. Berry, Douglas R. Osmon
The in vitro activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of ≥4 μg/ml. Three isolates had rifampin M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c37c35842beadab4aa08424fa8c1b2fc
https://europepmc.org/articles/PMC6811393/
https://europepmc.org/articles/PMC6811393/